25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ELDN (Eledon) Stock Analysis
Buy, Hold or Sell?

Let's analyze Eledon together

I guess you are interested in Eledon Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • 📊 Fundamental Analysis (FA) – Eledon’s Financial Insights
  • 📈 Technical Analysis (TA) – Eledon’s Price Targets

I'm going to help you getting a better view of Eledon Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Eledon Pharmaceuticals Inc

I send you an email if I find something interesting about Eledon Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Eledon (30 sec.)










1.2. What can you expect buying and holding a share of Eledon? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.37
Expected worth in 1 year
$2.89
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$1.52
Return On Investment
34.8%

For what price can you sell your share?

Current Price per Share
$4.36
Expected price per share
$3 - $4.98
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Eledon (5 min.)




Live pricePrice per Share (EOD)
$4.36
Intrinsic Value Per Share
$-10.71 - $-4.63
Total Value Per Share
$-9.33 - $-3.26

2.2. Growth of Eledon (5 min.)




Is Eledon growing?

Current yearPrevious yearGrowGrow %
How rich?$106m$60.2m$43.4m41.9%

How much money is Eledon making?

Current yearPrevious yearGrowGrow %
Making money$3.6m-$18.7m$22.4m613.4%
Net Profit Margin-2,904.8%-2,004.8%--

How much money comes from the company's main activities?

2.3. Financial Health of Eledon (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#317 / 843

Most Revenue
#599 / 843

Most Profit
#108 / 843

Most Efficient
#743 / 843
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Eledon?

Welcome investor! Eledon's management wants to use your money to grow the business. In return you get a share of Eledon.

First you should know what it really means to hold a share of Eledon. And how you can make/lose money.

Speculation

The Price per Share of Eledon is $4.36. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Eledon.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Eledon, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.37. Based on the TTM, the Book Value Change Per Share is $0.38 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.45 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Eledon.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.15-3.3%0.102.2%-0.31-7.2%-0.13-3.0%-0.13-3.0%-0.11-2.6%
Usd Book Value Change Per Share1.2328.1%0.388.7%-0.45-10.4%-0.09-2.1%0.061.4%0.000.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share1.2328.1%0.388.7%-0.45-10.4%-0.09-2.1%0.061.4%0.000.0%
Usd Price Per Share2.71-3.18-1.97-2.45-4.06-3.88-
Price to Earnings Ratio-4.66--26.55--2.16--10.65--11.54--11.42-
Price-to-Total Gains Ratio2.21-1.99--9.85--5.46--18.89-87.42-
Price to Book Ratio1.97-7.21--3.69-1.63-1.97-5.37-
Price-to-Total Gains Ratio2.21-1.99--9.85--5.46--18.89-87.42-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share4.36
Number of shares229
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.380.06
Usd Total Gains Per Share0.380.06
Gains per Quarter (229 shares)86.8013.95
Gains per Year (229 shares)347.2055.78
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1034733705646
206946840112102
30104210310167158
40138913780223214
50173617250279270
60208320720335326
70243024190390382
80277827660446438
90312531130502494
100347234600558550

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%1.046.00.02.1%
Book Value Change Per Share3.01.00.075.0%4.08.00.033.3%6.014.00.030.0%10.030.00.025.0%13.033.01.027.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.047.00.0%
Total Gains per Share3.01.00.075.0%4.08.00.033.3%6.014.00.030.0%10.030.00.025.0%13.033.01.027.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Eledon Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--1.2260.379+223%-0.453+137%-0.093+108%0.061+1913%0.000+100%
Book Value Per Share--1.3741.191+15%1.006+37%1.289+7%1.788-23%1.110+24%
Current Ratio--8.12010.242-21%15.478-48%12.232-34%18.469-56%13.833-41%
Debt To Asset Ratio--0.2680.307-13%0.383-30%0.255+5%0.210+28%0.164+64%
Debt To Equity Ratio--0.3670.446-18%0.160+129%0.230+60%0.548-33%0.343+7%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--277781944.280871734185.683-68%131565142.313+111%395589039.894-30%420324302.724-34%331821335.976-16%
Eps---0.1450.097-250%-0.314+116%-0.129-12%-0.132-9%-0.115-21%
Ev To Ebitda Ratio---2.808-28.023+898%-2.899+3%-11.774+319%-12.739+354%-15.112+438%
Free Cash Flow Per Share---0.230-0.191-17%-0.158-31%-0.161-30%-0.141-38%-0.113-51%
Free Cash Flow To Equity Per Share---0.2300.166-238%0.042-640%0.208-210%0.167-238%0.095-343%
Gross Profit Margin--1.0001.0040%1.005-1%1.0030%1.0020%1.078-7%
Intrinsic Value_10Y_max---4.634----------
Intrinsic Value_10Y_min---10.708----------
Intrinsic Value_1Y_max---0.455----------
Intrinsic Value_1Y_min---0.722----------
Intrinsic Value_3Y_max---1.374----------
Intrinsic Value_3Y_min---2.487----------
Intrinsic Value_5Y_max---2.302----------
Intrinsic Value_5Y_min---4.585----------
Market Cap261084539.000+20%209092944.280804877185.683-74%117817392.313+77%351328456.561-40%366280102.724-43%293984210.976-29%
Net Profit Margin----29.0480%-20.0480%-16.3650%-3687.5470%-1843.7730%
Operating Margin----16.0780%-6.4740%-7.5170%-3923.5680%-1961.7840%
Operating Ratio---16.203-100%6.517-100%7.574-100%3948.609-100%1974.304-100%
Pb Ratio3.173+38%1.9727.210-73%-3.689+287%1.632+21%1.9740%5.367-63%
Pe Ratio-7.498-61%-4.661-26.549+470%-2.164-54%-10.649+128%-11.544+148%-11.419+145%
Price Per Share4.360+38%2.7103.178-15%1.968+38%2.446+11%4.064-33%3.883-30%
Price To Free Cash Flow Ratio-4.748-61%-2.951-12.517+324%-3.309+12%-6.833+132%-10.601+259%-11.343+284%
Price To Total Gains Ratio3.557+38%2.2111.995+11%-9.845+545%-5.461+347%-18.886+954%87.418-97%
Quick Ratio--15.31519.022-19%26.800-43%19.313-21%22.506-32%15.954-4%
Return On Assets---0.0770.076-202%-0.171+121%-0.108+39%-0.083+8%-0.154+99%
Return On Equity---0.1060.118-190%-0.092-13%-0.074-30%-0.077-28%-0.168+59%
Total Gains Per Share--1.2260.379+223%-0.453+137%-0.093+108%0.061+1913%0.000+100%
Usd Book Value--106028000.000103701500.000+2%60268000.000+76%87991250.000+20%113541450.000-7%69681325.000+52%
Usd Book Value Change Per Share--1.2260.379+223%-0.453+137%-0.093+108%0.061+1913%0.000+100%
Usd Book Value Per Share--1.3741.191+15%1.006+37%1.289+7%1.788-23%1.110+24%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--277781944.280871734185.683-68%131565142.313+111%395589039.894-30%420324302.724-34%331821335.976-16%
Usd Eps---0.1450.097-250%-0.314+116%-0.129-12%-0.132-9%-0.115-21%
Usd Free Cash Flow---17713000.000-16132250.000-9%-9474250.000-47%-11218500.000-37%-9395100.000-47%-7246250.050-59%
Usd Free Cash Flow Per Share---0.230-0.191-17%-0.158-31%-0.161-30%-0.141-38%-0.113-51%
Usd Free Cash Flow To Equity Per Share---0.2300.166-238%0.042-640%0.208-210%0.167-238%0.095-343%
Usd Market Cap261084539.000+20%209092944.280804877185.683-74%117817392.313+77%351328456.561-40%366280102.724-43%293984210.976-29%
Usd Price Per Share4.360+38%2.7103.178-15%1.968+38%2.446+11%4.064-33%3.883-30%
Usd Profit---11216000.0003660750.000-406%-18794250.000+68%-12411666.667+11%-10728700.000-4%-8296250.000-26%
Usd Revenue---96000.000-100%140000.000-100%78666.667-100%65206.000-100%32603.000-100%
Usd Total Gains Per Share--1.2260.379+223%-0.453+137%-0.093+108%0.061+1913%0.000+100%
 EOD+6 -2MRQTTM+14 -21YOY+21 -143Y+13 -225Y+11 -2410Y+13 -22

3.3 Fundamental Score

Let's check the fundamental score of Eledon Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.498
Price to Book Ratio (EOD)Between0-13.173
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than115.315
Current Ratio (MRQ)Greater than18.120
Debt to Asset Ratio (MRQ)Less than10.268
Debt to Equity Ratio (MRQ)Less than10.367
Return on Equity (MRQ)Greater than0.15-0.106
Return on Assets (MRQ)Greater than0.05-0.077
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Eledon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4.370
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About Eledon Pharmaceuticals Inc

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney transplantation and xenotransplantation. The company has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Fundamental data was last updated by Penke on 2025-10-16 23:24:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Eledon earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,904.8%+2,904.8%
TTM-2,904.8%YOY-2,004.8%-900.0%
TTM-2,904.8%5Y-368,754.7%+365,849.9%
5Y-368,754.7%10Y-184,377.3%-184,377.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--78.6%+78.6%
TTM-2,904.8%-165.8%-2,739.0%
YOY-2,004.8%-186.4%-1,818.4%
3Y-1,636.5%-262.3%-1,374.2%
5Y-368,754.7%-338.6%-368,416.1%
10Y-184,377.3%-470.4%-183,906.9%
4.3.1.2. Return on Assets

Shows how efficient Eledon is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • -7.7% Return on Assets means that Eledon generated $-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eledon Pharmaceuticals Inc:

  • The MRQ is -7.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 7.6%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ-7.7%TTM7.6%-15.3%
TTM7.6%YOY-17.1%+24.7%
TTM7.6%5Y-8.3%+15.9%
5Y-8.3%10Y-15.4%+7.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.7%-11.9%+4.2%
TTM7.6%-11.5%+19.1%
YOY-17.1%-11.1%-6.0%
3Y-10.8%-12.0%+1.2%
5Y-8.3%-11.7%+3.4%
10Y-15.4%-13.8%-1.6%
4.3.1.3. Return on Equity

Shows how efficient Eledon is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • -10.6% Return on Equity means Eledon generated $-0.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eledon Pharmaceuticals Inc:

  • The MRQ is -10.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 11.8%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ-10.6%TTM11.8%-22.4%
TTM11.8%YOY-9.2%+21.0%
TTM11.8%5Y-7.7%+19.5%
5Y-7.7%10Y-16.8%+9.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.6%-14.0%+3.4%
TTM11.8%-14.7%+26.5%
YOY-9.2%-15.0%+5.8%
3Y-7.4%-16.6%+9.2%
5Y-7.7%-17.0%+9.3%
10Y-16.8%-19.4%+2.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Eledon Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Eledon is operating .

  • Measures how much profit Eledon makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,607.8%+1,607.8%
TTM-1,607.8%YOY-647.4%-960.4%
TTM-1,607.8%5Y-392,356.8%+390,749.0%
5Y-392,356.8%10Y-196,178.4%-196,178.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--164.9%+164.9%
TTM-1,607.8%-268.1%-1,339.7%
YOY-647.4%-244.8%-402.6%
3Y-751.7%-247.4%-504.3%
5Y-392,356.8%-331.9%-392,024.9%
10Y-196,178.4%-499.7%-195,678.7%
4.3.2.2. Operating Ratio

Measures how efficient Eledon is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM16.203-16.203
TTM16.203YOY6.517+9.686
TTM16.2035Y3,948.609-3,932.406
5Y3,948.60910Y1,974.304+1,974.304
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.898-1.898
TTM16.2032.730+13.473
YOY6.5172.820+3.697
3Y7.5743.559+4.015
5Y3,948.6094.571+3,944.038
10Y1,974.3046.270+1,968.034
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Eledon Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Eledon is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 8.12 means the company has $8.12 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 8.120. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.242. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ8.120TTM10.242-2.121
TTM10.242YOY15.478-5.236
TTM10.2425Y18.469-8.228
5Y18.46910Y13.833+4.636
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ8.1203.298+4.822
TTM10.2423.586+6.656
YOY15.4784.036+11.442
3Y12.2324.408+7.824
5Y18.4695.712+12.757
10Y13.8336.080+7.753
4.4.3.2. Quick Ratio

Measures if Eledon is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • A Quick Ratio of 15.31 means the company can pay off $15.31 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 15.315. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 19.022. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ15.315TTM19.022-3.707
TTM19.022YOY26.800-7.778
TTM19.0225Y22.506-3.484
5Y22.50610Y15.954+6.552
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.3152.912+12.403
TTM19.0223.185+15.837
YOY26.8003.852+22.948
3Y19.3134.393+14.920
5Y22.5065.692+16.814
10Y15.9546.457+9.497
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Eledon Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Eledon assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Eledon to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.27 means that Eledon assets are financed with 26.8% credit (debt) and the remaining percentage (100% - 26.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.268. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.307. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.268TTM0.307-0.039
TTM0.307YOY0.383-0.076
TTM0.3075Y0.210+0.097
5Y0.21010Y0.164+0.046
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2680.346-0.078
TTM0.3070.361-0.054
YOY0.3830.331+0.052
3Y0.2550.344-0.089
5Y0.2100.348-0.138
10Y0.1640.378-0.214
4.5.4.2. Debt to Equity Ratio

Measures if Eledon is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Eledon to the Biotechnology industry mean.
  • A Debt to Equity ratio of 36.7% means that company has $0.37 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eledon Pharmaceuticals Inc:

  • The MRQ is 0.367. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.446. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.367TTM0.446-0.079
TTM0.446YOY0.160+0.285
TTM0.4465Y0.548-0.103
5Y0.54810Y0.343+0.206
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3670.401-0.034
TTM0.4460.439+0.007
YOY0.1600.415-0.255
3Y0.2300.471-0.241
5Y0.5480.469+0.079
10Y0.3430.517-0.174
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Eledon generates.

  • Above 15 is considered overpriced but always compare Eledon to the Biotechnology industry mean.
  • A PE ratio of -4.66 means the investor is paying $-4.66 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eledon Pharmaceuticals Inc:

  • The EOD is -7.498. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.661. Based on the earnings, the company is expensive. -2
  • The TTM is -26.549. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.498MRQ-4.661-2.838
MRQ-4.661TTM-26.549+21.889
TTM-26.549YOY-2.164-24.385
TTM-26.5495Y-11.544-15.005
5Y-11.54410Y-11.419-0.125
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.498-2.909-4.589
MRQ-4.661-2.358-2.303
TTM-26.549-2.715-23.834
YOY-2.164-3.615+1.451
3Y-10.649-3.803-6.846
5Y-11.544-5.965-5.579
10Y-11.419-6.965-4.454
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eledon Pharmaceuticals Inc:

  • The EOD is -4.748. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.951. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -12.517. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.748MRQ-2.951-1.797
MRQ-2.951TTM-12.517+9.566
TTM-12.517YOY-3.309-9.208
TTM-12.5175Y-10.601-1.916
5Y-10.60110Y-11.343+0.742
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.748-3.570-1.178
MRQ-2.951-2.941-0.010
TTM-12.517-3.869-8.648
YOY-3.309-4.368+1.059
3Y-6.833-5.330-1.503
5Y-10.601-8.302-2.299
10Y-11.343-9.974-1.369
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Eledon is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.97 means the investor is paying $1.97 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Eledon Pharmaceuticals Inc:

  • The EOD is 3.173. Based on the equity, the company is fair priced.
  • The MRQ is 1.972. Based on the equity, the company is underpriced. +1
  • The TTM is 7.210. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD3.173MRQ1.972+1.201
MRQ1.972TTM7.210-5.238
TTM7.210YOY-3.689+10.899
TTM7.2105Y1.974+5.236
5Y1.97410Y5.367-3.393
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.1732.426+0.747
MRQ1.9722.064-0.092
TTM7.2102.243+4.967
YOY-3.6892.491-6.180
3Y1.6322.682-1.050
5Y1.9743.805-1.831
10Y5.3674.462+0.905
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Eledon Pharmaceuticals Inc.

4.8.1. Institutions holding Eledon Pharmaceuticals Inc

Institutions are holding 72.859% of the shares of Eledon Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-06-30Bvf Inc10.50950.6093629328200
2025-06-30RA Capital Management, LLC5.95560.1628356633800
2025-06-30Vanguard Group Inc5.54160.0002331838336525612.3684
2025-06-30BlackRock Inc5.43430.000232541522601531398.6281
2025-06-30First Light Asset Management, LLC4.34270.9137260049827173011.6684
2025-06-30Sphera Funds Management Ltd.3.27251.24621959610-347509-15.0625
2025-06-30Woodline Partners LP2.79190.0239167182200
2025-06-30Geode Capital Management, LLC2.31110.00031383940717223107.5753
2025-06-30Blue Owl Capital Holdings LP2.22091.16311329912-490000-26.9244
2025-06-30Ensign Peak Advisors Inc2.11240.0059126491900
2025-06-30Nantahala Capital Management, LLC1.90580.1212114123700
2025-06-30Awm Investment Company Inc1.83770.3344110047300
2025-06-30Susquehanna International Group, LLP1.70160.00041018919-566729-35.7412
2025-06-30Ikarian Capital, LLC1.67030.52061000221-25000-2.4385
2025-06-30Schonfeld Strategic Advisors LLC1.66740.0184998454-320388-24.2931
2025-06-30Zimmer Partners LP1.63770.057898068222571229.8968
2025-06-30Alyeska Investment Group, L.P.1.55890.008993347500
2025-06-30Sanofi1.3611.256781498000
2025-06-30Siren, L.L.C.1.15260.096869017000
2025-06-3022NW, LP1.06271.085963636400
Total 60.04827.626735957831+2431826+6.8%

4.9.2. Funds holding Eledon Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-07-31Vanguard Total Stock Mkt Idx Inv3.07850.00031843489-40654-2.1577
2025-08-31iShares Russell 2000 ETF2.30810.0054138212800
2025-07-31Vanguard Institutional Extnd Mkt Idx Tr1.11850.0026669788-305203-31.3032
2025-06-30Fidelity Small Cap Index0.9730.00625826275826270
2025-08-31iShares Russell 2000 Value ETF0.7960.010547666500
2025-07-31Fidelity Extended Market Index0.53870.0026322597-2654-0.816
2025-06-30MEDICAL BioHealth EUR Acc0.49180.120329448500
2025-07-31Vanguard Russell 2000 ETF0.46570.007278859-19425-6.5123
2025-08-31State St Russell Sm Cap® Indx SL Cl I0.34530.005620680000
2025-07-31Schwab Small Cap Index0.24590.007114726200
2025-06-30NT R2000 Index Fund - NL0.23680.00621417871417870
2025-08-31iShares Micro-Cap ETF0.22150.03813261100
2025-06-30Extended Equity Market Fund K0.19890.0022119120-2378-1.9572
2025-07-31Fidelity Total Market Index0.18930.0003113345-241-0.2122
2025-06-30NT R2000 Index Fund - DC - NL - 30.18880.00621130451130450
2025-07-31iShares Russell 2000 Small-Cap Idx Instl0.16960.007310154600
2025-06-30Russell 2500™ Index Fund F0.1560.002493413934130
2025-07-31Fidelity Series Total Market Index0.14040.00038406000
2025-07-31Nuveen Small Cap Blend Idx R60.12740.00717629200
2025-07-31Spartan Extended Market Index Pool F0.12360.00267403326543.7182
Total 12.11380.24027253952+562971+7.8%

5.3. Insider Transactions

Insiders are holding 1.396% of the shares of Eledon Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2021-12-20David-alexandre C GrosBUY20004.48
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in USD. All numbers in thousands.

Summary
Total Assets144,909
Total Liabilities38,881
Total Stockholder Equity106,028
 As reported
Total Liabilities 38,881
Total Stockholder Equity+ 106,028
Total Assets = 144,909

Assets

Total Assets144,909
Total Current Assets111,404
Long-term Assets33,505
Total Current Assets
Cash And Cash Equivalents 5,741
Short-term Investments 101,829
Net Receivables 705
Other Current Assets 3,129
Total Current Assets  (as reported)111,404
Total Current Assets  (calculated)111,404
+/-0
Long-term Assets
Property Plant Equipment 773
Intangible Assets 32,386
Long-term Assets Other 346
Long-term Assets  (as reported)33,505
Long-term Assets  (calculated)33,505
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities13,719
Long-term Liabilities25,162
Total Stockholder Equity106,028
Total Current Liabilities
Short-term Debt 672
Accounts payable 5,831
Other Current Liabilities 7,216
Total Current Liabilities  (as reported)13,719
Total Current Liabilities  (calculated)13,719
+/-0
Long-term Liabilities
Capital Lease Obligations 803
Long-term Liabilities  (as reported)25,162
Long-term Liabilities  (calculated)803
+/- 24,359
Total Stockholder Equity
Common Stock60
Retained Earnings -373,297
Other Stockholders Equity 423,619
Total Stockholder Equity (as reported)106,028
Total Stockholder Equity (calculated)50,382
+/- 55,646
Other
Capital Stock60
Cash and Short Term Investments 107,570
Common Stock Shares Outstanding 77,156
Liabilities and Stockholders Equity 144,909
Net Debt -4,938
Net Invested Capital 50,334
Net Working Capital 97,685
Property Plant and Equipment Gross 773
Short Long Term Debt Total 803



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-30
> Total Assets 
0
32,287
0
23,420
106,983
107,744
96,650
87,410
77,607
67,974
57,710
46,857
36,721
29,761
25,831
26,844
23,019
20,892
25,917
22,965
19,928
17,026
13,451
18,216
15,218
10,931
13,720
10,501
192,585
197,185
191,682
184,305
177,170
170,548
161,378
154,706
149,586
92,793
82,306
106,785
96,069
125,894
80,818
120,483
114,576
177,405
161,308
144,909
144,909161,308177,405114,576120,48380,818125,89496,069106,78582,30692,793149,586154,706161,378170,548177,170184,305191,682197,185192,58510,50113,72010,93115,21818,21613,45117,02619,92822,96525,91720,89223,01926,84425,83129,76136,72146,85757,71067,97477,60787,41096,650107,744106,98323,420032,2870
   > Total Current Assets 
0
32,178
0
21,739
106,724
107,511
96,332
86,756
76,865
67,170
56,987
46,186
36,334
29,543
25,631
24,843
21,035
19,000
24,028
21,078
17,110
14,276
10,321
15,181
12,296
9,971
12,873
9,761
115,101
115,630
110,241
102,582
95,558
88,346
79,325
72,788
67,565
59,518
48,904
73,622
62,991
56,129
47,977
87,221
81,509
143,730
127,718
111,404
111,404127,718143,73081,50987,22147,97756,12962,99173,62248,90459,51867,56572,78879,32588,34695,558102,582110,241115,630115,1019,76112,8739,97112,29615,18110,32114,27617,11021,07824,02819,00021,03524,84325,63129,54336,33446,18656,98767,17076,86586,75696,332107,511106,72421,739032,1780
       Cash And Cash Equivalents 
0
31,753
0
21,150
105,464
105,256
94,162
59,084
33,168
24,023
14,303
12,156
18,630
23,223
24,400
22,498
19,094
17,233
22,523
19,189
16,324
12,972
9,056
13,703
10,814
8,791
11,785
8,764
114,464
114,195
108,579
101,133
94,041
84,833
76,677
70,460
65,889
56,409
46,485
40,947
3,667
4,612
5,655
26,039
6,751
20,549
8,496
5,741
5,7418,49620,5496,75126,0395,6554,6123,66740,94746,48556,40965,88970,46076,67784,83394,041101,133108,579114,195114,4648,76411,7858,79110,81413,7039,05612,97216,32419,18922,52317,23319,09422,49824,40023,22318,63012,15614,30324,02333,16859,08494,162105,256105,46421,150031,7530
       Short-term Investments 
0
0
0
0
0
0
0
24,110
39,935
39,934
39,947
31,771
16,088
4,175
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30,431
55,942
46,490
37,207
57,571
71,440
119,629
116,385
101,829
101,829116,385119,62971,44057,57137,20746,49055,94230,43100000000000000000000000024,17516,08831,77139,94739,93439,93524,1100000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
594
747
739
956
245
247
162
214
110
197
87
0
0
0
0
0
0
0
0
0
0
0
0
0
0
761
705
7057610000000000000087197110214162247245956739747594000000000000000000000
       Other Current Assets 
0
425
0
589
1,260
2,255
2,170
3,562
3,762
3,213
2,737
4,518
1,616
2,145
1,231
2,345
3,882
0
1,505
1,889
786
710
518
739
526
935
841
835
423
1,325
1,465
1,362
1,517
3,513
2,648
2,328
1,676
3,109
2,419
2,244
3,382
5,027
5,115
3,611
3,318
3,552
2,076
3,129
3,1292,0763,5523,3183,6115,1155,0273,3822,2442,4193,1091,6762,3282,6483,5131,5171,3621,4651,3254238358419355267395187107861,8891,50503,8822,3451,2312,1451,6164,5182,7373,2133,7623,5622,1702,2551,26058904250
   > Long-term Assets 
0
109
0
1,681
259
233
318
654
742
804
723
671
387
218
200
2,001
1,984
1,892
1,889
1,887
2,818
2,750
3,130
3,035
2,922
960
847
740
77,484
81,555
81,441
81,723
81,612
82,202
82,053
81,918
82,021
33,275
33,402
33,163
33,078
69,765
32,841
33,262
33,067
33,675
33,590
33,505
33,50533,59033,67533,06733,26232,84169,76533,07833,16333,40233,27582,02181,91882,05382,20281,61281,72381,44181,55577,4847408479602,9223,0353,1302,7502,8181,8871,8891,8921,9842,0012002183876717238047426543182332591,68101090
       Property Plant Equipment 
0
29
0
36
38
33
73
339
427
489
453
401
117
98
80
49
47
25
22
20
17
14
458
413
367
321
275
229
183
138
92
267
222
768
675
581
832
739
647
553
459
365
270
621
471
926
850
773
77385092647162127036545955364773983258167576822226792138183229275321367413458141720222547498098117401453489427339733338360290
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,867
1,867
1,867
1,867
1,867
1,867
1,867
1,867
1,867
1,867
0
0
0
44,466
48,648
48,648
48,648
48,648
48,648
48,648
48,648
48,648
0
0
0
0
0
0
0
0
0
0
0
0000000000048,64848,64848,64848,64848,64848,64848,64848,64844,4660001,8671,8671,8671,8671,8671,8671,8671,8671,8671,867000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,386
32,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,38632,3860000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
639
0
511
33,018
32,907
315
422
356
400
344
303
155
0
0
224
0
0
0
0
0
0
0
0
000000002240015530334440035642231532,90733,01851106390000000000000000000000000
> Total Liabilities 
0
87,554
0
3,688
5,372
4,243
5,754
4,660
5,708
6,250
6,303
7,973
6,464
2,903
2,467
3,405
2,400
1,440
1,619
1,452
1,603
2,534
3,522
2,184
1,852
1,466
1,975
1,145
171,079
6,589
7,811
5,784
6,422
6,553
5,060
5,327
8,493
8,610
7,514
6,836
4,734
42,475
5,999
128,984
38,518
59,265
46,728
38,881
38,88146,72859,26538,518128,9845,99942,4754,7346,8367,5148,6108,4935,3275,0606,5536,4225,7847,8116,589171,0791,1451,9751,4661,8522,1843,5222,5341,6031,4521,6191,4402,4003,4052,4672,9036,4647,9736,3036,2505,7084,6605,7544,2435,3723,688087,5540
   > Total Current Liabilities 
0
2,209
0
3,688
5,372
4,243
5,754
4,647
5,657
6,162
6,177
7,817
6,344
2,819
2,419
3,160
2,306
1,440
1,619
1,452
1,603
2,534
3,241
1,948
1,661
1,322
1,878
1,097
6,130
2,483
4,206
2,677
4,046
4,401
2,958
3,276
6,280
6,475
5,478
4,900
2,899
3,895
4,247
6,025
12,489
11,577
9,185
13,719
13,7199,18511,57712,4896,0254,2473,8952,8994,9005,4786,4756,2803,2762,9584,4014,0462,6774,2062,4836,1301,0971,8781,3221,6611,9483,2412,5341,6031,4521,6191,4402,3063,1602,4192,8196,3447,8176,1776,1625,6574,6475,7544,2435,3723,68802,2090
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
3
3,447
0
0
0
0
0
0
0
0
340
346
354
180
368
376
382
288
194
358
354
738
656
574
756
726
768
780
792
383
284
538
372
628
650
672
672650628372538284383792780768726756574656738354358194288382376368180354346340000000003,4473000000000000
       Accounts payable 
0
5
0
1,216
2,889
765
3,434
1,704
1,652
1,208
1,886
1,846
886
338
276
374
189
0
449
706
751
689
480
753
256
329
741
150
758
1,366
1,514
857
1,598
1,813
1,026
1,318
3,859
2,200
2,852
2,197
465
967
1,864
2,148
5,860
5,833
2,901
5,831
5,8312,9015,8335,8602,1481,8649674652,1972,8522,2003,8591,3181,0261,8131,5988571,5141,36675815074132925675348068975170644901893742763388861,8461,8861,2081,6521,7043,4347652,8891,216050
       Other Current Liabilities 
0
2,204
0
2,472
2,483
3,478
2,320
2,943
4,005
4,954
4,291
5,971
5,458
-966
2,143
2,786
2,117
0
1,170
746
852
1,845
2,421
849
1,051
813
769
571
4,990
829
2,498
1,462
2,094
1,850
1,276
1,384
1,665
3,549
1,858
1,923
1,642
2,545
2,099
3,339
6,257
5,116
5,634
7,216
7,2165,6345,1166,2573,3392,0992,5451,6421,9231,8583,5491,6651,3841,2761,8502,0941,4622,4988294,9905717698131,0518492,4211,8458527461,17002,1172,7862,143-9665,4585,9714,2914,9544,0052,9432,3203,4782,4832,47202,2040
   > Long-term Liabilities 
0
85,345
0
0
0
0
0
13
51
88
126
156
120
84
48
245
94
0
1,170
746
852
1,845
281
236
191
144
97
48
164,949
4,106
3,605
3,107
2,376
2,152
2,102
2,051
2,213
2,135
2,036
1,936
1,835
38,580
1,752
122,959
26,029
47,688
37,543
25,162
25,16237,54347,68826,029122,9591,75238,5801,8351,9362,0362,1352,2132,0512,1022,1522,3763,1073,6054,106164,94948971441912362811,8458527461,17009424548841201561268851130000085,3450
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,106
3,605
3,017
2,331
1,752
1,752
1,752
1,752
0
0
1,752
0
0
0
0
0
0
0
0
000000001,752001,7521,7521,7521,7522,3313,0173,6054,10600000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,752
0
0
0
0
0
0
0
0
0
0000000001,75200000000000000000000000000000000000000
> Total Stockholder Equity
0
-55,267
0
19,732
101,611
103,501
90,896
82,750
71,899
61,724
51,407
38,884
30,257
26,858
23,364
23,439
20,619
0
24,298
21,513
18,325
14,492
9,929
16,032
13,366
9,465
11,745
9,356
21,506
190,596
183,871
178,521
170,748
163,995
156,318
149,379
141,093
84,183
74,792
99,949
91,335
83,419
74,819
-8,501
76,058
118,140
114,580
106,028
106,028114,580118,14076,058-8,50174,81983,41991,33599,94974,79284,183141,093149,379156,318163,995170,748178,521183,871190,59621,5069,35611,7459,46513,36616,0329,92914,49218,32521,51324,298020,61923,43923,36426,85830,25738,88451,40761,72471,89982,75090,896103,501101,61119,7320-55,2670
   Common Stock
0
0
0
15
22
22
22
22
23
23
23
23
23
23
23
7
7
0
9
9
9
9
9
13
13
13
16
19
1
15
14
14
14
14
14
14
14
14
14
23
24
24
25
39
41
60
60
60
606060413925242423141414141414141414151191613131399999077232323232323232222222215000
   Retained Earnings Total Equity000000000-213,63700000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
-43
0
0
-106,983
-58
0
-2
8
-55
-5
6
3
-1
-3
0
0
0
0
0
0
0
0
0
0
0
0
0
-90,460
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
102
26
-18
-48
-48-1826102000000000000000-90,4600000000000000-3-136-5-558-20-58-106,98300-430
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
288,415
0
0
0
0
0
0
0
0
0
000000000288,41500000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
7,831
0
93,470
181,732
189,830
190,485
191,298
192,289
193,194
194,253
195,245
195,891
196,233
196,604
45,858
46,008
0
54,601
55,005
55,313
56,054
56,372
66,564
66,791
67,034
77,488
77,682
-68,955
270,974
272,749
274,783
276,827
278,880
281,067
283,375
285,560
287,034
288,415
323,142
324,876
326,586
328,280
379,400
386,884
473,640
476,619
423,619
423,619476,619473,640386,884379,400328,280326,586324,876323,142288,415287,034285,560283,375281,067278,880276,827274,783272,749270,974-68,95577,68277,48867,03466,79166,56456,37256,05455,31355,00554,601046,00845,858196,604196,233195,891195,245194,253193,194192,289191,298190,485189,830181,73293,47007,8310



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-359
Gross Profit-359-359
 
Operating Income (+$)
Gross Profit-359
Operating Expense-70,218
Operating Income-70,577-70,577
 
Operating Expense (+$)
Research Development51,964
Selling General Administrative18,613
Selling And Marketing Expenses0
Operating Expense70,21870,577
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-70,577
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-35,753-105,401
EBIT - interestExpense = -35,753
-34,891
-35,322
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-35,753-35,753
Earnings Before Interest and Taxes (EBITDA)-35,394
 
After tax Income (+$)
Income Before Tax-35,753
Tax Provision-431
Net Income From Continuing Ops-36,184-36,184
Net Income-35,322
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses70,577
Total Other Income/Expenses Net34,8240
 

Technical Analysis of Eledon
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Eledon. The general trend of Eledon is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Eledon's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Eledon Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Eledon Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 4.86 < 4.965 < 4.98.

The bearish price targets are: 4.085 > 3.95 > 3.

Know someone who trades $ELDN? Share this with them.👇

Eledon Pharmaceuticals Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eledon Pharmaceuticals Inc. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Eledon Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartEledon Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Eledon Pharmaceuticals Inc. The current adx is .

Eledon Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartEledon Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Stochastic Oscillator ChartEledon Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartEledon Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartEledon Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Williams %R ChartEledon Pharmaceuticals Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Average True Range (ATR) ChartEledon Pharmaceuticals Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartEledon Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartEledon Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Eledon Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-06-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-06-17STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-06-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-07-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-03CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-07-08BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-07-09RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-18RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-07-23STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-07-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-07-29DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-08-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-08-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-18WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-25STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-08-29STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-09-08STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-10STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-09-11DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-09-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-09-15STOCH SHORT EXITThe %K line crosses above the %D line.
2025-09-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-09-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-09-23STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-09-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-09-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-10-03BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-10-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-07MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-10-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-10-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-10-10STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-10-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-10-16SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-10-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-10-21STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-10-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-10-24STOCH SHORT EXITThe %K line crosses above the %D line.
2025-10-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-30MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Eledon Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Eledon Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose4.370
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Eledon with someone you think should read this too:
  • Are you bullish or bearish on Eledon? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Eledon? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Eledon Pharmaceuticals Inc

I send you an email if I find something interesting about Eledon Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Eledon Pharmaceuticals Inc.

Receive notifications about Eledon Pharmaceuticals Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.